Klin Farmakol Farm. 2018;32(3):11-14 | DOI: 10.36290/far.2018.017

Vedolizumab, its pharmacological profile and therapeutic use

Tomáš Douda
II. interní gastroenterologická klinika, Subkatedra gastroenterologie, Lékařská fakulta UK, Centrum pro idiopatické střevní záněty, Fakultní nemocnice Hradec králové

Vedolizumab (VDZ), a humanized monoclonal antibody, is approved for use in ulcerative colitis and Crohn’s disease (IBD).Vedolizumabinhibits leukocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. Clinicaleffectiveness of vedolizumab was evident in both the CD and mainly in UC populations. These findings are consistent withobservations from clinical trials, and from real word experience too. The improved safety profile, novel mechanism of action andclinical need for new therapies has led to the rapid adoption of vedolizumab use in clinical practice.

Keywords: vedolizumab, Crohn’s disease, ulcerative colitis, biologic therapy

Published: November 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Douda T. Vedolizumab, its pharmacological profile and therapeutic use. Klin Farmakol Farm. 2018;32(3):11-14. doi: 10.36290/far.2018.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Neurath M. Cytokines in inflammatory bowel disease. Nature Reviews. 2014; 14: 329-342. Go to original source... Go to PubMed...
    2. Dave M, et al. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin N Am. 2014; 43: 405-424. Go to original source... Go to PubMed...
    3. Burisch J, et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis 2013. 7(4): 322-337. Go to original source... Go to PubMed...
    4. Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015; 50(8): 942-951. Go to original source...
    5. Bortlík M, Ďuricová D, Kohout P, et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: třetí, aktualizované vydání. Gastroenterologie a hepatologie. 2016; 70(1): 11-26. Go to original source...
    6. Lukáš M. Perspektivy biologické léčby u idiopatických střevních zánětů. Gastroenterologie a hepatologie 2014; 68(3): 225-229.
    7. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68-72. Go to original source...
    8. Sheridan BS, Lefrancois L. Regional and mucosal memory T cells. Nat Immunol. 2011; 12(6): 485-491. Go to original source...
    9. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330(3): 864-875. Go to original source... Go to PubMed...
    10. Sandborn, WJ. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925. Go to original source...
    11. Danese S, Panés J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. J. Gastroenterology 2014; 147: 981-989. Go to original source...
    12. von Andrian UH, et al. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343(14): 1020-1034. Go to original source...
    13. Van Assche, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. NEJM 2005; 353(4): 362-368. Go to original source... Go to PubMed...
    14. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61: 35-47. Go to original source... Go to PubMed...
    15. Tan C, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9: 425-437. Go to original source...
    16. Lazarovits AI, Moscicki RA, Kurnick JT, et al. Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol 1984; 133(4): 1857-1862. Go to original source...
    17. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996; 111(5): 1373-1380. Go to original source...
    18. Feagan BG, McDonald J, Greenberg G, et al. An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis. Gastroenterology 2000; 118: A874. Go to original source...
    19. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352: 2499-2507. Go to original source...
    20. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-1377. Go to original source...
    21. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18: 1470-1479. Go to original source... Go to PubMed...
    22. Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing ?4?7 itegrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol 2013; 264(1-2): 123-126. Go to original source... Go to PubMed...
    23. Rietdijk ST, D'Haens GR. Vedolizumab for the treatment of ulcerative colitis. Expert Rev Clin Pharmacol 2014; 7(4): 423-430. Go to original source... Go to PubMed...
    24. Bortlík M. Vedolizumab - nová antiintegrinová protilátka s vysokou gastrointestinální selektivitou. Gastroent Hepatol 2014; 68(6): 481-484. Go to original source...
    25. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369(8): 699-710. Go to original source... Go to PubMed...
    26. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369(8): 711-721. Go to original source... Go to PubMed...
    27. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147(3): 618-627. Go to original source...
    28. Amiot A, et al. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients with Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2016; 14(11): 1593-1601. Go to original source...
    29. Fleisher M, et al. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Dig Dis Sci. 2018; 63(4): 825-833. Go to original source...
    30. Feagan BG, et al. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. Journal of Crohn's and Colitis, jjy125, https://doi.org/10.1093/ecco-jcc/jjy125
    31. Dulai, PS, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY Consortium. Am. J. Gastroenterol. 2016; 111: 1147-1155. Go to original source... Go to PubMed...
    32. Stallmach A, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment. Pharmacol. Ther. 2016; 44: 1199-1212. Go to original source... Go to PubMed...
    33. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2016; 0: 1-13.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.